This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment

This study has been completed.
Solvay Pharmaceuticals
Information provided by:
Mclean Hospital Identifier:
First received: March 16, 2006
Last updated: November 17, 2010
Last verified: November 2010

We hypothesize that AndroGel may offer some relief to subjects with low or borderline testosterone levels who suffer from depression and have failed to respond to a trial of a standard antidepressant.

During this nine week, outpatient, double-blind study, male subjects between the ages of 30 and 65 years with treatment-refractory depression and low or borderline low testosterone levels will be treated with either AndroGel or placebo. Following this nine week, double-blind phase, eligible subjects will have the option to continue into a six month, open-label phase during which time all subjects will receive the AndroGel patch.

Condition Intervention Phase
Depressive Disorder, Major Drug: Testosterone gel Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Parallel-Group, Placebo-Controlled Trial of AndroGel in Men With Major Depressive Disorder Who Display an Incomplete Response to Standard Antidepressant Treatment

Resource links provided by NLM:

Further study details as provided by Mclean Hospital:

Primary Outcome Measures:
  • 21-item Hamilton Depression Rating Scale Score (HAM-D) [ Time Frame: 9 weeks (1-week placebo lead-in and 8 weeks of blinded medication treatment) ]
    The HAM-D generates a score ranging from 0 (no depressive symptoms) to 64 (most severe depression).

Secondary Outcome Measures:
  • Montgomery Asberg Depression Rating Scale (MADRS) [ Time Frame: 9 weeks (1 week of placebo lead-in and 8 weeks of blinded medication treatment) ]
    The Montgomery Asberg Depression Rating Scale (MADRS) is a clinician-assessed scale that rates depressive symptoms on a scale from 0 (no depressive symptoms) to 60 (maximal depressive symptoms).

Enrollment: 100
Study Start Date: April 2006
Study Completion Date: April 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: testosterone gel
AndroGel (1% testosterone transdermal gel), 2.5 g to 10 g daily
Drug: Testosterone gel
AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
Other Name: AndroGel
Placebo Comparator: placebo gel
Placebo gel
Drug: Placebo

Detailed Description:
We will recruit 100 men between the ages of 30 and 65 years who have treatment-refractory depression and low or borderline low testosterone levels for participation in this study. For a period of nine weeks subjects will receive double-blind treatment with either AndroGel (testosterone gel) or placebo. During this double-blind treatment phase subjects will come to McLean Hospital for a total of seven visits. Both clinical assessments (including ratings of your levels of depression and anxiety, quality of life, and visuospatial memory)and laboratory tests will be performed at these visits. Following the nine week, double-blind phase, eligible subjects may enter into a six month, open-label treatment phase in which all subject receive AndroGel. If you participate in the open-label phase, you will be asked to return to the site for 8 visits during the six month period.

Ages Eligible for Study:   30 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male
  • 30-65 years old
  • Taking at least one serotonergic antidepressant at adequate dose for at least six weeks but still meeting DSM-IV criteria for major depressive disorder within the past year
  • HAM-D score >12

Exclusion Criteria:

  • Current suicidal ideation
  • Substance abuse or dependence within the past year
  • Current or past psychotic symptoms
  • A history of bipolar disorder
  • A prostate-specific antigen (PSA) level greater than 4.0 ng/ml
  • Other clinically significant medical condition
  • A history of failing to show any clinically significant response to two or more adequate trials of different antidepressants.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00304746

United States, Massachusetts
McLean Hospital
Belmont, Massachusetts, United States, 02478
The Chaim Sheba Medical Center
Tel-Hashomer, Israel, 52621
Sponsors and Collaborators
Mclean Hospital
Solvay Pharmaceuticals
Principal Investigator: Harrison G Pope, M.D. Mclean Hospital
Principal Investigator: Stuart N Seidman, M.D. Columbia University
  More Information

Responsible Party: Harrison G. Pope, Jr., M.D., McLean Hospital Identifier: NCT00304746     History of Changes
Other Study ID Numbers: 2005P-001667
Study First Received: March 16, 2006
Results First Received: September 24, 2010
Last Updated: November 17, 2010

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Antidepressive Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents
Psychotropic Drugs processed this record on September 19, 2017